

# Asbestos

## Raising the Bar in Asbestos Litigation

PAGE 5

### Asbestos is Not the Only Known Cause of Mesothelioma

A Commentary from Edward R. Hugo of Hugo Parker LLP

PAGE 9

### Parties in Cosmetic Talc Case Reach Settlement Before Opening Arguments

PAGE 10

### J&J Asks U.S. Supreme Court to Review Talc-Related Securities Dispute

PAGE 23

### 5<sup>th</sup> Circuit Schedules Argument in Appeal of EPA's Final Rule on Chrysotile Asbestos

12

MDL Court Says Further  
Delay in Beasley Allen  
Decision 'Not Warranted'

13

Calif. Trial Court Vacates  
\$950 Million Punitive  
Damage Awards in Talc Case

18

Vanderbilt Minerals Files  
Chapter 11 Bankruptcy  
Under Weight of Talc Claims

20

Virginia Court Grants Motion  
For Sanctions in Talc Trade  
Libel Case Against Kradin

22

Court Weighs in on Privilege  
Of Documents in DBMP  
Proceedings

25

9<sup>th</sup> Circuit Reverses Order on  
Common Carrier Exception  
In Libby, Mont., Appeal

# COLUMNS

March 2026 • Vol. 26, No. 3

## EDITORIAL STAFF

Publisher/Editorial Director  
*Jeff Andrus*

Managing Editor  
*Kate McGovern Ferriola*

Editor  
*Marcy Kowalchuk*

## BUSINESS STAFF

Conference Director  
*Vicki Gilbreath*

Circulation Manager  
*Alison Murphy*

## Editorial Correspondence

Article submissions and news should be forwarded to Kate McGovern Ferriola, Managing Editor, HarrisMartin Publishing. E-mail: [kmcgovern@harrismartin.com](mailto:kmcgovern@harrismartin.com)

HarrisMartin's *COLUMNS-Asbestos* is published monthly by HarrisMartin Publishing LLC  
P.O. Box 10  
Haddonfield, NJ 08033  
*\$975 print & online annual subscription*  
*\$595 print & online 6-month subscription*

Questions or subscription requests can be directed to [service@harrismartin.com](mailto:service@harrismartin.com) or call (610) 647-5500.

## Advertising Sales

Questions or interest in advertising in *COLUMNS-Asbestos* can be directed to Jeff Andrus at (610) 647-5500.

Copyright © 2026 by HarrisMartin Publishing LLC. All rights reserved. All stories written by HarrisMartin editorial staff unless otherwise noted. Opinions expressed by contributors are their own and not necessarily those of HarrisMartin Publishing or its editorial staff. **No part of this publication may be reproduced by any means, electronic or mechanical, including photocopying, without written permission from HarrisMartin Publishing.**

[www.harrismartin.com](http://www.harrismartin.com)

## PERSPECTIVES

Asbestos is Not the Only Known Cause of Mesothelioma 2  
by Edward R. Hugo of Hugo Parker LLP

## TABLE OF CASES

A Regional Listing of All the Cases Covered in This Issue 8

## COURTROOM NEWS

Calif. Court Enters \$24.4 Million Judgment Against Talc Defendant 9  
Parties in Cosmetic Talc Case Reach Settlement Before Opening Arguments 9  
Parties Reach Settlement After Opening Statements in Cosmetic Talc Trial 10  
J&J Asks U.S. Supreme Court to Review Talc-Related Securities Dispute 10  
J&J Defendants Oppose Beasley Allen's Attempts to Appeal Disqualification Order 11  
MDL Court Says Further Delay in Beasley Allen Decision 'Not Warranted' 12  
Calif. Trial Court Vacates \$950 Million Punitive Damage Awards in Talc Case 13  
N.J. Supreme Court Denies Request to Stay Talc Docket 14  
Court Releases Opinion Allowing Pecos River Talc to File Amended Complaint 14  
PSC Responds to Objections to Report Allowing Testimony Linking Talc, Ovarian Cancer 15  
2<sup>nd</sup> Circuit Hears Arguments in Revlon Bankruptcy Appeal Involving Future Claimants 17  
Beasley Allen Files Request for Stay in Appellate Division in Disqualification Dispute 18  
Vanderbilt Minerals Files Chapter 11 Bankruptcy Under Weight of Talc Claims 18  
Court: Pecos River Talc's Efforts to Obtain Third-Party Funding Details 'Untimely' 19  
Virginia Court Grants Motion for Sanctions in Talc Trade Libel Case Against Kradin 20  
Missouri Appellate Court Affirms Verdict in Favor of Defendant 21  
Calif. Court Affirms Summary Judgment Award to City of San Diego 21  
Court Weighs in on Privilege of Documents in DBMP Proceedings 22  
5<sup>th</sup> Circuit Schedules Argument in Appeal of EPA's Final Rule on Chrysotile Asbestos 23  
Del. Court Rejects Post-Trial Motions Contesting \$9 Million Shotgun Shell Verdict 23  
Court Denies Motion to Remand Case, Finds Defendant Fraudulently Joined 24  
N.C. Court Finds No Reason to Disturb Bestwall Bankruptcy Court's Order 25  
9<sup>th</sup> Circuit Reverses Order on Common Carrier Exception in Libby, Mont., Appeal 25  
6<sup>th</sup> Circuit Reverses Order Dismissing Declaratory Judgement Action 26

## VERDICT REPORT

A Listing of the Last Year of Asbestos Verdicts 27



# Asbestos is *Not* the Only *Known* Cause of Mesothelioma

*A Commentary by Edward R. Hugo of Hugo Parker LLP*

*Author bio on page 6*

It is now *known* that additional causes of mesothelioma include exposure to other types of mineral fibers (such as erionite), radiation and naturally occurring mesothelioma arising in the setting of pathogenic germline mutations, also known as gene-related mesothelioma.<sup>1</sup> Cancers are caused by the accumulation of genetic mutations that may be inherited, induced by environmental factors, or as a result of DNA replication errors (*i.e.*, spontaneous cell division errors).<sup>2</sup> Like other cancers, “irrespective of exposure and of inherited mutations, some mesotheliomas may occur because of the inevitable accumulation of spontaneous mutations... .”<sup>3</sup>

The evidence supporting the existence of “gene-related malignant mesotheliomas” that are unrelated to asbestos exposure includes the following: (1) lack of temporal relation between mesothelioma in women and historic use of commercial forms of asbestos (*i.e.*, the age-adjusted mesothelioma incidence in U.S. women from 1973 to 2008 has been stable while the commercial use of asbestos has dramatically declined); (2) the occurrence of mesothelioma in children aged below the lowest recorded latent period for occupational asbestos-associated mesotheliomas; (3) cases of mesothelioma in persons with no history of asbestos exposure despite extensive investigation and/or with no detectable fibers in a fiber burden analysis; and (4) the spontaneous occurrence of various cancers, including mesothelioma, in animals.<sup>4</sup>

Plaintiffs’ counsel argue that their clients with genetic germline variants (or “mutations”) are “egg shell” plaintiffs, *i.e.*, that they are merely *more susceptible* to asbestos causing their mesothelioma than the average person. However, that is merely an argument because there is no evidence that a background level of exposure to asbestos can inactivate the suppressor genes that result in mesothelioma in humans. A recent animal study comparing the rate of spontaneous mesotheliomas in mice with and without germline genetic mutations in the absence of asbestos exposure refutes the “egg shell” plaintiff argument.<sup>5</sup> And, historical observations of mesothelioma developing in different animals demonstrates that the disease is naturally occurring:

Mesotheliomas have been found sporadically in nonexperimental settings in at least eight different animal species, including *fish* (*bass*-Harshbarger, 1965-1973; *trout* - Herman, 1985); *wild rats* (Norvegicus-McCoy, 1909; Woolley and Wherry, 1911); *hamsters* (Arnold *et al.*, 1976; Mehnert *et al.*, 1974; Fortner, 1961); *mastomys* (Solleveld, 1978; Solleveld *et al.*, 1984); *domestic* (Ilgren *et al.*, 1982) and *wild dogs* (Stewart, 1964); *leopards* (Ilgren *et al.*, 1982); *eland*s (Ilgren *et al.*, 1982); and *adult* (Baskerville, 1967) Purmann, 1930; Misdorp, 1963; Grant, 1958; Smith and Jones, 1957). *neonatal* (Grant,

1958), and *fetal* (Henschen and Alegrin, 1927; Drieux *et al.*, 1949) *cows*.<sup>6</sup>

Cancer predisposition syndromes are caused by inherited pathogenic mutations in tumor suppressor genes.<sup>7</sup> BRCA1 Associated Protein-1 (“BAP1”) is located on chromosome 3 and acts as a tumor suppressor, meaning that it helps prevent cells from growing uncontrollably and turning into cancer. The BAP1 tumor suppressor gene regulates tumorigenesis at two stages: initiation and progression. At the first stage, loss or inactivating mutations of BAP1 impairs its ability to repair DNA damage and to induce apoptosis (natural programmed cell death) resulting in accumulation of genetic mutations, genomic instability and the initiation of cancer. At the second stage, loss of BAP1 function allows the cancer cells to revive their metabolism to promote growth, survival and proliferation, including tumor metastasis.<sup>8,9</sup> Thus, BAP1 tumor predisposition syndrome (“TPDS”) causes “gene-related malignant mesothelioma” in the absence of asbestos exposure and is a distinct etiology from asbestos-related malignant mesothelioma.<sup>10 11 12 13 14 15 16</sup>

Checkpoint Kinase 2 (“CHEK2”) is a tumor suppressor gene that encodes the protein CHK2. It is located on chromosome 22 and like BAP1 is involved in DNA repair, cell cycle arrest and apoptosis in response to DNA damage. Mesothelial cells are continually subjected to endogenous sources of DNA damage, even without exposure to asbestos,

including replication stress, reactive oxygen species generated by cellular metabolism and transcription-replication conflicts.<sup>17</sup> Normally, CHK2 senses such insults and either prevents proliferation to permit cell repair or terminates damaged cells by apoptosis.<sup>18-20</sup> But, cells expressing CHEK2 result in attenuated checkpoint activation, incomplete cell cycle arrest and reduced apoptosis after genotoxic stress.<sup>21-23-24</sup> Thus, like a mutant BAP1 gene a mutant CHEK2 gene can drive mesothelioma in the absence of asbestos exposure.

The differences between gene-related malignant mesothelioma (“GR-MM”) and asbestos-related malignant mesothelioma (“AR-MM”) include the following:

**Asbestos Exposure:**

GR-MM: develops in the absence of exposure above ambient levels.

AR-MM: develops in response to exposure above ambient levels.

**Latency:**

GR-MM: occurs in children aged below the lowest recorded latency period for AR-MM.

AR-MM: occurs after a generally accepted minimum latency of 10 years.

**Age at Diagnosis:**

GR-MM: Median age is approximately 55.

AR-MM: Median age is approximately 72.

**Gender Susceptibility:**

GR-MM: Male to female ratio of 1:1.

AR-MM: Male to female ratio of 5:1.

*“...Coupled with advances in genomics, it is now known that pathogenic germline mutations, in the absence of asbestos exposure, cause malignant mesothelioma.”*

**Site Distribution:**

GR-MM: Pleural to peritoneal ratio of 1:1.

AR-MM: Pleural to peritoneal ratio of 10:1.

**Initial Clinical Symptoms:**

GR-MM: Minimal to asymptomatic.

AR-MM: Serious and progressive.

**Histology/Morphology:**

GR-MM: Usually low grade epithelioid subtype with rare mitosis, minimal necrosis and early superficial invasion.

AR-MM: Histology includes epithelioid, sarcomatoid and biphasic subtypes with aggressive features and higher mitosis and necrosis.

**Survival:**

GR-MM: Median survival of 6 years with some patients surviving over 20 years.

AR-MM: Median survival of 16 months with virtually no long-term survivors.

**Conclusion**

The differences in asbestos exposure, latency, age at diagnosis, gender susceptibility, site distribution, clinical symptoms, histology/morphology and survival demonstrate that GR-MM and AR-MM are different diseases with different causes. Coupled with advances in genomics, it is now *known* that pathogenic germline mutations, *in the absence of asbestos exposure*, cause malignant mesothelioma.

**Footnotes**

<sup>1</sup> Attanoos, R.L., et al., “Malignant Mesothelioma and Its Non-Asbestos causes,” *Arch. Pathol. Lab. Med.*, 142:753-760 (2018).

<sup>2</sup> Tomasetti, C., Li, L., Vogelstein, B., “Stem Cell Divisions, Somatic Mutations, Cancer Etiology, and Cancer Prevention,” *Science*, 355:1330-34 (2017).

<sup>3</sup> Carbone, M., et al., “Mesothelioma: Scientific Clues for Prevention, Diagnosis and Therapy,” *Can. Cancer J. Clin.*, 69:402-429 (2019).

<sup>4</sup> Attanoos, R.L., et al., “Malignant Mesothelioma and Its Non-Asbestos causes,” *Arch. Pathol. Lab. Med.*, 142:756-757 (2018).

<sup>5</sup> Nielsen D.M., Hsu M., Zapata M. 3rd, Ciavarrà G., van Zyl L., Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP 1 mutant mice in the absence of asbestos exposure, *Sci. Rep.* (Jan 2, 2025), 15(1 ): 169 (“Our analysis concurs with the biological data showing that pathogenic germline BAP1 mutations are sufficient to cause malignant mesothelioma independent of external factors (i.e., exposure to asbestos)”).

<sup>6</sup> E.B. & Wagner, J.C. (1991) “Background Incidence of Mesothelioma: Animal and Human Evidence,” *Regulatory Toxicology and Pharmacology* 13, pp. 133-149.

<sup>7</sup> Machida, Y.J. (2019) “A mechanism for the tissue specificity in BAP1 cancer syndrome,” *Translational Cancer Research*, 8(Suppl 6), pp. S621-S624.

<sup>8</sup> Elsiayed, A.M. et al. (2025) “An overview of BAP1 biological functions and current therapeutics,” *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer*, 1880(2), p. 189267.

<sup>9</sup> Liberti, M.V. and Locasale, J.W. (2016) “The Warburg Effect: How Does it Benefit Cancer Cells?,” *Trends Biochem Sci.* 41(3); pp. 211-218.

<sup>10</sup> Carbone, M. et al. (2025) “Clinical and Pathologic Phenotyping of mesotheliomas developing in carriers of Germline BAP1 Mutations,” *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, pp. S 1556-0864(25)00808-1.

<sup>11</sup> Congedo, M.T. et al. (2024) “The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review,” *Journal of Thoracic Disease*, 16(1), pp. 671-687.

<sup>12</sup> Galateau-Salle, F. et al. (2023) “Mesothelioma In Situ Mimicking Well-differentiated Papillary Mesothelial Tumor,” *The American Journal of Surgical Pathology*, 47(5), pp. 611-617.

<sup>13</sup> Ghafoor, A., Perez, C.O. and Hassan, R. (2025) “Germline BAP1 Mutation-Associated Mesothelioma: A Biologically and Clinically Distinct Entity,” *Journal of Thoracic Oncology*, 20(11), pp. 1577-1579.

<sup>14</sup> Novelli, F. et al. (2024) “Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling,” *Proceedings of the National Academy of Sciences*, 121 (29), p. e2405231121.

<sup>15</sup> Nielsen, D.M. et al. (2025) “Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP1 mutant mice in the absence of asbestos exposure,” *Scientific Reports*, 15(1), p. 169.

<sup>16</sup> Wu, X. et al. (2025) “Prospective Analysis of Mesotheliomas in Subjects with BAP1 Cancer Syndrome: Clinical Characteristics and Epigenetic Correlates of Disease,” *Journal of Thoracic Oncology*, p. S1556086425009840.

<sup>17</sup> Jackson, S.P. and Bartek, J. (2009) “The DNA-damage response in human biology and disease,” *Nature*, 461(7267), pp. 1071-1078.

<sup>18</sup> Hirao, A. et al. (2000) “DNA damage-induced activation of p53 by the checkpoint kinase Chk2,” *Science* (New York, N.Y.), 287 (5459), pp. 1824-1827.

<sup>19</sup> Bartek, J. and Lukas, J. (2003) “Chk1 and Chk2 kinases in checkpoint control and cancer,” *Cancer Cell*, 3(5), pp. 421-429.

<sup>20</sup> Matsuokak, S. et al. (2007) “ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage,” *Science*, 316(5828), pp. 1160-1166.

<sup>21</sup> Bell, D.W. et al. (2007) “Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts,” *International Journal of Cancer*, 121(12), pp. 2661-2667.

<sup>22</sup> Boonen, R.A.C.M. et al. (2022) “Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk,” *Cancer Research*, 82(4), pp. 615-631.

<sup>23</sup> Cybulski, C. et al. (2004) “CHEK2 is a multiorgan cancer susceptibility gene,” *American Journal of Human Genetics*, 75(0), pp. 1131-1135.

<sup>24</sup> McCarthy-Leo, C.E. et al. (2024) “Comprehensive analysis of the functional impact of single nucleotide variants of human CHEK2,” *PLoS genetics*, 20(8), p. e1011375.



**EDWARD R. HUGO** is a trial attorney, appellate lawyer, litigator and litigation manager for cases involving products and premises liability, toxic torts, environmental claims, construction defect, personal injury, wrongful death, insurance, professional negligence, sexual molestation and criminal law. He has also been

retained as an expert witness and testified in trial, arbitration and deposition regarding: the duties of defense counsel, the effectiveness of defense strategies, the reasonableness of settlement values and defense costs, and insurance coverage issues.

See <https://hugoparker.com/edward-hugo/>